5-[4-(3,4-difluoro-benzoylamino)-phenylamino]-2-oxo-4-phenyl-1,2-dihydro-1,8-naphthyridine-3-carboxylic acid (2-hydroxy-ethyl)-amide | 1203510-13-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-[4-(3,4-difluoro-benzoylamino)-phenylamino]-2-oxo-4-phenyl-1,2-dihydro-1,8-naphthyridine-3-carboxylic acid (2-hydroxy-ethyl)-amide
• 英文别名: 5-[4-[(3,4-difluorobenzoyl)amino]anilino]-N-(2-hydroxyethyl)-2-oxo-4-phenyl-1H-1,8-naphthyridine-3-carboxamide
• CAS: 1203510-13-7
• 化学式: C₃₀H₂₃F₂N₅O₄
• 分子量: 555.541
• InChiKey: PMHQCAOTQCKLJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  41
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  132
• 氢给体数：
  5
• 氢受体数：
  8

文献信息

• [EN] NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS<br/>[FR] NAPHTYRIDININONES EN TANT QU'INHIBITEURS D'AURORA KINASE
  申请人：MERCK SERONO SA

  公开号：WO2010002779A2

  公开（公告）日：2010-01-07

  Naphthyridinone derivative compounds that inhibit Aurora kinase enzymes are disclosed along with pharmaceutical compositions comprising these compounds and methods for synthesizing the same. Such compounds have utility in the treatment of proliferative diseases resulting from unregulated and/or disturbed Aurora kinases such as cancers, psoriasis, viral and bacterial infections, inflammatory and autoimmune diseases.